الفهرس 
EPIDEMIOLOGY
Differentiation pathways of lymphocytesOnly 14 pages are availabe for public view
 |  | from | 196 |  |  |
| | | from | 196 | | |
Abstract
This work is a prospective study to compare between R-CHOP and CHOP as chemotherapy treatment in newly diagnosed patients with Diffuse Large B cell Non-Hodgkin’s Lymphoma,to asses the role of rituximab as front line treatment in these patients. Our study included 50 patients, they were divided into two groups A and B, each group contain 25 patients, the patients in group A received 6 cycles CHOP 21 while in group B they received 6 cycles R-CHOP 21. We assessed the response after finishing the 6th cycle, 68% of the patients in group B achieved CR, while 44% of the patients in group A achieved CR. The response was also compared between the two groups according to the IPI, the percentage of the patients with low IPI who achieved CR in group A was 75% and in group B was 73%,while in high IPI the percentage of the patients who achieved CR in group B was much higher than that in group B, with 60% versus 15% in group A.